Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

9. Check if this filing amends a previously filed version of this report

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code BUD

16. Specific lobbying issues

H.R. 4368: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024
H.R. 5893: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2024
H.R. 5894: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024
H.R. 2670: National Defense Authorization Act for Fiscal Year 2024
S. 2226: National Defense Authorization Act for Fiscal Year 2024
S. 2131: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024
S. 2321: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2024
S. 2624: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024
FY 2024 President's Budget Request
Inflation Reduction Act of 2022 (P.L. 117-169)
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (P.L. 117-180)

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CPT

16. Specific lobbying issues

H.R. 1717: Interagency Patent Coordination and Improvement Act of 2023
H.R. 4370: PREVAIL Act - Provisions related to the PTAB
H.R. 4692: Increasing Prescription Drug Competition Act - Patent-related policy issues
H.R. 5429: Medication Affordability and Patent Integrity Act
H.R. 5475: Prohibiting Adversarial Patents Act of 2023
H.R. 6275: Protecting Consumer Access to Generic Drugs Act of 2023 - Patent-related policy issues
H.R. 6436: Stopping Pharmas Ripoffs and Drug Savings For All Act - Patent-related policy issues
H.R. 6684: Improving Efficiency to Increase Competition Act - Patent-related policy issues
S. 79: Interagency Patent Coordination and Improvement Act of 2023
S. 142: Preserve Access to Affordable Generics and Biosimilars Act - Provisions related to patent settlements
S. 150: Affordable Prescriptions for Patients Act of 2023 - Provisions related to intellectual property and patents
S. 574: Increasing Prescription Drug Competition Act - Patent-related policy issues
S. 2140: Patent Eligibility Restoration Act of 2023 - Provisions related to patents
S. 2220: PREVAIL Act - Provisions related to the PTAB
S. 2780: Medication Affordability and Patent Integrity Act
Biopharmaceutical innovation and patent policy issues
Bayh-Dole march-in rights policy issues
Request for Information Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights (Docket No.: 230831-0207)
Patent thicket policy issues
Patent use codes policy issues

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

H.R. 167: Patient Access to Urgent-Use Pharmacy Compounding Act of 2023
H.R. 198: Drug Pricing Transparency and Accountability Act - Provisions related to the 340B Program
H.R. 456: Fairness in Orphan Drug Exclusivity Act
H.R. 830: HELP Copays Act - To amend title XXVII of the Public Health Service Act to apply additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans, and for other purposes
H.R. 885: TRACK Act of 2023
H.R. 1503: Prescription Information Modernization Act of 2023
H.R. 1613: Drug Price Transparency in Medicaid Act of 2023
H.R. 1790: Biologics Competition Act of 2023 - To direct the Secretary of Health and Human Services to evaluate the extent to which the substitution of interchangeable biological products is impacted by differences between the system for determining a biological product to be interchangeable and the system for assigning therapeutic equivalence ratings to drugs, and for other purposes
H.R. 2408: Access to Innovative Treatments Act of 2023
H.R. 2500: Protecting Americans from Unsafe Drugs Act of 2023
H.R. 2534: PROTECT 340B Act of 2023 - Provisions related to the 340B program
H.R. 2679: Pharmacy Benefits Manager Accountability Act
H.R. 2707: MADE in America Act
H.R. 2816: Pharmacy Benefit Manager Sunshine and Accountability Act
H.R. 2880: Protecting Patients Against PBM Abuses Act
H.R. 2893: Seniors Securing Access to Vital and Essential Prescription Drugs Act
H.R. 2959: Health Savings Act of 2023
H.R. 3008: Drug Shortage Prevention Act of 2023
H.R. 3093: Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2023
H.R. 3134: Emergency Access to Insulin Act of 2023
H.R. 3160: Pharmaceutical Research Transparency Act of 2023
H.R. 3281: Transparent PRICE Act
H.R. 3284: Providers and Payers COMPETE Act
H.R. 3285: Fairness for Patient Medications Act
H.R. 3290: To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program
H.R. 3433: Give Kids a Chance Act of 2023
H.R. 3561: Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or PATIENT Act of 2023
H.R. 3791: Improving DATA in Public Health Act
H.R. 3793: Ensuring Access to Lifesaving Drugs Act of 2023
H.R. 3810: Drug Origin Transparency Act of 2023
H.R. 3839: To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications
H.R. 4115: Lower Drug Costs for Families Act
H.R. 4421: Preparing for All Hazards and Pathogens Reauthorization Act
H.R. 4507: Transparency in Coverage Act of 2023
H.R. 4508: Hidden Fee Disclosure Act of 2023
H.R. 4822: Health Care Price Transparency Act of 2023
H.R. 4882: Clinical Laboratory Price Transparency Act of 2023
H.R. 4895: Lowering Drug Costs for American Families Act - Provisions related to drug pricing
H.R. 4988: Modern Authentication of Pharmaceuticals Act of 2023
H.R. 5376: Share the Savings with Seniors Act
H.R. 5378: Lower Costs, More Transparency Act
H.R. 5391: Protecting Patient Access to Cancer and Complex Therapies Act
H.R. 5539: ORPHAN Cures Act
H.R. 5547: Maintaining Investments in New Innovation Act
H.R. 6283: Delinking Revenue from Unfair Gouging or DRUG Act
S. 113: Prescription Pricing for the People Act of 2023 - Provisions related to PBMs
S. 127: Pharmacy Benefit Manager Transparency Act of 2023 - Provisions related to PBMs
S. 148: Stop STALLING Act - Provisions related to citizen petitions
S. 315: Taxpayer Research And Contributions Knowledge Act of 2023 or TRACK Act of 2023 - To direct the Secretary of Health and Human Services and other Federal officials to compile into a searchable database information relating to Federal support for biomedical research and development, and for other purposes
S. 476: Maintaining Investments in New Innovation Act
S. 775: Increasing Transparency in Generic Drug Applications Act
S. 935: Fair Accountability and Innovative Research Drug Pricing Act of 2023 - Provisions related to drug pricing
S. 954: Affordable Insulin Now Act of 2023
S. 1067: Ensuring Timely Access to Generics Act of 2023
S. 1114: Expanding Access to Low-Cost Generics Act 2023
S. 1130: Health Care PRICE Transparency Act
S. 1128: Ensuring Access to Generic Medications Act
S. 1214: RARE Act - To set forth limitations on exclusive approval or licensure of drugs designated for rare diseases or conditions
S. 1217: Prescription Drug Impact Act of 2023
S. 1250: Drug-price Transparency for Consumers Act of 2023
S. 1264: SMART Prices Act - Provisions related to drug pricing reform
S. 1339: Pharmacy Benefit Manager Reform Act - Provisions related to PBMs
S. 1355: PASTEUR Act of 2023 - Provisions related to antimicrobial resistance policy issues
S. 1374: Patient Right to Shop Act
S. 1375: HELP Copays Act - To amend title XXVII of the Public Health Service Act to apply additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans, and for other purposes
S. 1476: Pharmaceutical Research Transparency Act of 2023
S. 1497: Emergency Access to Insulin Act of 2023
S. 1542: Delinking Revenue from Unfair Gouging Act or DRUG Act - Provisions related to PBMs
S. 1589: Safeguarding Patients and Taxpayers Act
S. 1906: Promising Pathway Act - Approval pathway policy issues
S. 1967: PBM Act
S. 2305: Biosimilar Red Tape Elimination Act
S. 2333: Pandemic and All-Hazards Preparedness and Response Act
S. 2456: Protecting Seniors from High Drug Costs Act
S. 2474: Share the Savings with Seniors Act
S. 2840: Bipartisan Primary Care and Health Workforce Act
S. 2973: Modernizing and Ensuring PBM Accountability Act (MEPA)
S. 3393: SUPPORT for Patients and Communities Reauthorization Act
S. 4953: Protect Drug Innovation Act
User fee policy issues
Inflation Reduction Act of 2022 (P.L. 117-169)
Nomination of Dr. Monica Bertagnolli as NIH director
Pharmacy Benefit Manager reform and policy issues
Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA)
Cancer Moonshot Initiative
21st Century Cures 2.0
Drug cost and pricing policy issues
Principles for drug pricing reform
Drug importation policy issues
Accelerated approval policy issues
FDA regulatory approval authority policy issues
Competition policy issues
Orphan Drug Act policy issues
Antimicrobial resistance (AMR) policy issues
High deductible health plans/HSA policy issues
Supply chain policy issues
Mental health policy issues
Real world evidence policy issues
Clinical trial diversity policy issues
Prescription drug abuse policy issues
340B drug discount program policy issues
Patient assistance program policy issues
Biosimilar approval and reimbursement policy issues
Drug shortages policy issues
COVID-19 policy issues
Pandemic preparedness policy issues
Cybersecurity policy issues
Anticounterfeiting policy issues
Artificial intelligence policy issues

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Centers For Medicare and Medicaid Services (CMS)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

H.R. 133: MERIT Act
H.R. 485: Protecting Health Care for All Patients Act of 2023 - To amend title XI of the Social Security Act to prohibit the use of quality-adjusted life years and similar measures in coverage and payment determinations under Federal health care programs
H.R. 2666: Medicaid VBPs for Patients Act or MVP Act
H.R. 3421: Medicare for All Act
S. 1491: Pharmacy and Medically Underserved Areas Enhancement Act
S. 1450: Cutting Medicare Prescription Drug Prices in Half Act
Inflation Reduction Act of 2022 (P.L. 117-169)
Part D redesign and policy issues including non-interference and rebates policy issues
Part B policy issues
Drug cost and pricing policy issues
Rebate policy issues
Insulin policy issues
Value-based purchasing arrangements policy issues
Anti-Kickback Statute policy issues
Center for Medicare and Medicaid Innovation (CMMI) and model policy issues
CMMI Cell and Gene Therapy Access Model
Medicaid rebates and waiver policy issues
CMS Guidance on the Medicare Drug Price Negotiation Program: Initial Memorandum [ ] IPAY 2026 and Solicitation of Comments
CMS Medicare Drug Price Negotiation Revised Guidance
CMS Guidance on Medicare Part B and D Inflation Rebates
Medicaid Drug Rebate Program Proposed rule (CMS-2434-P)

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TRD

16. Specific lobbying issues

H.R. 405: Essential Medicines Strategic Stockpile Act of 2023
H.R. 447: MMEDS Act of 2023
H.R. 4307: Medical Supply Chain Resiliency Act
H.R. 3858: No Free TRIPS Act
S. 845: Short on Competition Act
S. 1834: No Free TRIPS Act
S. 2115: Medical Supply Chain Resiliency Act
Biopharmaceutical innovation policy issues
International intellectual property and market access policy issues
Pricing and reimbursement policy issues
Supply chain policy issues
WTO TRIPS waiver policy issues
China outbound investment policy issues

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different than line 20)

22. New General description of client’s business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issue that no longer pertains

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address: http://www.phrma.org/about/members

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities:

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

CONVICTIONS DISCLOSURE

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
No Yes